CAR-T（CAR-T）细胞疗法在非肿瘤性疾病中的应用
Chimeric antigen receptor T (CAR-T) cell therapy in non-oncological diseases.
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
CAR-T 细胞治疗后继发性血液肿瘤的罕见性与风险
英文原题：Rarity & Risk of Secondary Hematologic Neoplasms after CAR T-cell Therapies.
查看英文原题
Rarity & Risk of Secondary Hematologic Neoplasms after CAR T-cell Therapies.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
摘要
这条来源本身就没有摘要（PubMed 未提供），不是「还没翻译」。可以点最下面的「在 PubMed 查看」打开原文献页面。
论文信息
- 作者
- Hamilton MP、Alizadeh AA
- 第一作者单位
- Division of Oncology, Department of Medicine, Stanford University School of Medicine, Stanford, CA 94305, USA; Center for Cancer Cell Therapy, Stanford Cancer Institute, Stanford University School of Medicine, Stanford, CA 94305, USA; Division of Blood and Marrow Transplantation and Cellular Therapy, Department of Medicine, Stanford University School of Medicine, Stanford, CA 94305, USA.United States
- 通讯作者单位
- Division of Oncology, Department of Medicine, Stanford University School of Medicine, Stanford, CA 94305, USA; Stanford Cancer Institute, Stanford University, Stanford, CA, 94305, USA; Institute for Stem Cell Biology and Regenerative Medicine, Stanford University, Stanford, CA, 94305, USA.United States
- 期刊
- Transplantation and cellular therapy2024 Oct
- 原文标识
- PubMed 39326982 · DOI 10.1016/j.jtct.2024.09.002